AVITA Medical, Inc. Stock

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-10 pm EDT 5-day change 1st Jan Change
8.26 USD -5.17% Intraday chart for AVITA Medical, Inc. -5.60% -39.80%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 115M 76.08M Sales 2025 * 164M 108M Capitalization 323M 213M
Net income 2024 * -56M -36.94M Net income 2025 * -17M -11.22M EV / Sales 2024 * 2.63 x
Net cash position 2024 * 19.8M 13.06M Net cash position 2025 * 1.85M 1.22M EV / Sales 2025 * 1.96 x
P/E ratio 2024 *
-5.67 x
P/E ratio 2025 *
-28.5 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.3%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day-5.17%
1 week-5.60%
Current month-1.67%
1 month-20.19%
3 months-54.11%
6 months-26.84%
Current year-39.80%
More quotes
1 week
7.97
Extreme 7.9672
9.64
1 month
7.97
Extreme 7.9672
10.20
Current year
7.97
Extreme 7.9672
18.93
1 year
7.97
Extreme 7.9672
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
24-05-10 8.26 -5.17% 329,508
24-05-09 8.71 -2.79% 368,469
24-05-08 8.96 -4.38% 371,776
24-05-07 9.37 +5.28% 171,445
24-05-06 8.9 +1.71% 131,256

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.51 AUD
Average target price
39.74 AUD
Spread / Average Target
+217.66%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW